TP53 and colorectal carcinoma: Among the broad cancer cell lines including colorectal, hepatic, breast, and lung cancers, naphplatin exhibits lower IC50 values in colorectal carcinoma (90 nM for HT-29, 60 nM for HCT-116 and 30 nM for CT-26) than the other cancer cells, which are in accordance with the results of the cellular drug uptake and DNA platinization by ICP-MS (Fig. S44a), flow cytometry scatter plots and up-regulated p53 in vitro (Fig. S44b-e).